IRON DEFICIENCY ANEMIA IN PREGNANCY INTRAVENOUS IRON SUCROSE AN ALTERNATIVE TO ORAL FERROUS SULPHATE THERAPY
Shireen A¹, S. Radhamani²

HOW TO CITE THIS ARTICLE:
Shireen A, S. Radhamani. "Iron Deficiency Anemia in Pregnancy Intravenous Iron Sucrose an Alternative to Oral Ferrous Sulphate Therapy". Journal of Evolution of Medical and Dental Sciences 2014; Vol. 3, Issue 57, October 30; Page: 13014-13029, DOI: 10.14260/jemds/2014/3728

ABSTRACT: BACKGROUND AND OBJECTIVE: Iron deficiency anemia in pregnancy is a commonest medical problem throughout the developing world with the burden of disease impacting in both mother and newborn. Anaemia affects nearly half of all the pregnant women in the world, these figures are 52% in the developing and 23% in the developed world. The high prevalence of iron deficiency anaemia among women during pregnancy in developing countries is of concern and a cause of considerable morbidity and mortality. The aim of the study is to know whether intravenous iron sucrose can be an better alternative in terms of safety, efficacy and compliance over oral ferrous sulphate in the treatment of anaemia in pregnancy. METHOD: This prospective study is conducted in Obstetrics & Gynaecology Department of Cheluvamba hospital, Mysore Medical College and Research Institute, Mysore. All these women are randomly assigned (100 women each) to receive either calculated dose of intravenous iron sucrose (Group B) or oral ferrous sulphate 200mg BD per day (Group A). Hemoglobin, hematocrit and mean corpuscular estimation is done before treatment and after 4wks of correction in both groups to note the improvement in values and monitored for adverse reactions. OBSERVATIONS AND RESULTS: The percentage rise in hemoglobin is statistically significant when baseline hemoglobin levels are compared with that at fourth week of treatment. Statistically significant rise in hemoglobin, hematocrit and mean corpuscular levels are found at fourth week in IV group when compared to oral group. None of the patients had any serious side effects. There were no treatment failures and none of them required blood transfusions. CONCLUSION: This study concluded that intravenous iron sucrose is safe, highly efficacious with better compliance for the treatment of iron deficiency anemia in pregnancy. Iron sucrose therapy is more effective in achieving the optimum results, an increase in hemoglobin concentration, mean corpuscular volume levels and an increase in hematocrit %. Therefore it is a suitable alternative to oral iron. KEYWORDS: Iron Sucrose, Pregnancy, Hemoglobin.

METHODOLOGY: The study titled —Iron deficiency Anemia in Pregnancy: Intravenous iron sucrose an alternative to oral ferrous sulphate therapy‖ is conducted in the Department of Obstetrics and Gynaecology, Cheluvamba Hospital, MMCRI, Mysore.

AIMS AND OBJECTIVES: To study the efficacy, safety and compliance of intravenous iron sucrose as compared to oral ferrous sulphate in the treatment of iron deficiency anemia in pregnancy.

INCLUSION CRITERIA:
1. Singleton pregnancy.
2. 16 to 32 wks of gestation.
3. Hb % 7 to 10.9g%.
4. Willingness to enrollment to study.

EXCLUSION CRITERIA:
1. Non-iron deficient anemia.
2. Hb% < 7g%.
3. Reactions to i.v iron sucrose.
4. H/o blood transfusion in present pregnancy.
5. H/o intake of iron in any form orally.
6. High risk pregnancy.

METHODOLOGY: This is a prospective study conducted on pregnant women of 16 to 32wks of gestation according to inclusion criteria in 18months of study period (2011-2013). The patients are selected after explaining in detail about study design and written consent is taken. The study is conducted in outpatient basis

  Group A (n=A) oral ferrous sulphate group.
  Group B (n=B) iv iron sucrose group.

VISIT 1: Thorough history is elicited and clinical examination is done. Complete hemogram is done to know pre-treatment Hb%, MCV, Hct along with that peripheral smear asked to rule out non-iron deficient anemias and stool examination for occult blood, cyst and ova. Both group are given a dose of Tab. Albendazole 400mg before commencing therapy.

GROUP A: They received ferrous sulphate orally 200mg containing 60mg of elemental iron BD for 4wks after food.

GROUP B: They received iron sucrose intravenously dose depending on the formula 2.4 x Hb deficit in gm% x body weight in kgs. It is given in divided doses, 200mg each time with minimum 48hrs apart. Each ml contained 20mg of elemental iron. Every 5ml of it is dissolved in 100ml of 0.9% of NS. Per day maximum of 200mg infusion is given. No test dose is given. If there are any adverse reactions, then drip is stopped and treated. Injections given on outpatient basis, no admissions required.

VISIT 2: The patient are questioned about compliance and examined again for general conditions. The complete hemogram is repeated to know the post treatment response.

STATISTICAL METHODS APPLIED:
FREQUENCIES: The Frequencies procedure provides statistics and graphical displays that are useful for describing many types of variables. The Frequencies procedure is a good place to start looking at your data.

DESCRIPTIVE: The Descriptives procedure displays univariate summary statistics for several variables in a single table and calculates standardized values (z scores). Variables can be ordered by
the size of their means (in ascending or descending order), alphabetically, or by the order in which you select the variables (the default).

**CROSSTABS (CONTINGENCY COEFFICIENT TEST):** The Crosstabs procedure forms two-way and multiway tables and provides a variety of tests and measures of association for two-way tables. The structure of the table and whether categories are ordered determine what test or measure to use.

**INDEPENDENT-SAMPLES T TEST:** The Independent-Samples T Test procedure compares means for two groups of cases. Ideally, for this test, the subjects should be randomly assigned to two groups, so that any difference in response is due to the treatment (or lack of treatment) and not to other factors.

**REPEATED MEASURE ANOVA:** Repeated Measures analyzes groups of related dependent variables that represent different measurements of the same attribute. This dialog box lets you define one or more within-subjects factors for use in GLM Repeated Measures. Note that the order in which you specify within-subjects factors is important. Each factor constitutes a level within the previous factor. All the statistical calculations were done through SPSS 16.0 (2007) for windows.

**OBSERVATIONS AND RESULTS:** This randomized trial is conducted in Obstetrics & Gynaecology Department, Cheluvamba hospital, Mysore Medical College and Research Institute, Mysore. The aim of the study is to know the response of intravenous iron sucrose with that of oral ferrous sulphate in terms of safety, efficacy and compliance of intravenous iron sucrose over oral ferrous sulphate in the treatment of iron deficiency anaemia in pregnancy. All these women were randomly assigned (100 women each) to receive either calculated dose of intravenous iron sucrose (Group B) or oral ferrous sulphate 200mg BD per day (Group A).

### TABLE 1: AGewise DISTRIBUTION OF CASES

| Age in Years | GROUP | Total |
|--------------|-------|-------|
|              | Count | % | Count | % | Count | % |
| 16-20        | 30    | 30% | 39    | 39% | 69    | 34.5% |
| 21-25        | 49    | 49% | 34    | 46% | 95    | 47.5% |
| 26-30        | 18    | 18% | 11    | 11% | 29    | 14.5% |
| 31-35        | 3     | 3%  | 4     | 4%  | 7     | 3.5%  |
| **Total**    | 100   | 100%| 100   | 100%| 200   | 100% |
Table 1 shows age-wise distribution of cases. Mean age in group A is 22.7±3.4 and in group B is 22.3±3.6 which is statistically insignificant. No patients from either group discontinued the study.

Table 2: Distribution of patients according to booking status

| Booking Status | GROUP          | Total |
|----------------|----------------|-------|
|                | Group A  | Group B |      |
| B              | Count    |  82     |  84  | 166 |
| % of GROUP     | 82.0%    | 84.0%   | 83.0%|
| UB             | Count    |  18     |  16  |  34 |
| % of GROUP     | 18.0%    | 16.0%   | 17.0%|
| Total          | Count    | 100     | 100  | 200 |
| % of GROUP     | 100.0%   | 100.0%  | 100.0%|

Table 2 shows 82 patients in group A and 84 patients in group B are booked cases out of 100 patients each and remaining are unbooked. This is statistically insignificant.
TABLE 3: DISTRIBUTION OF PATIENTS ACCORDING TO GRAVIDITY

| GRAVIDA | GROUP       | Total |
|---------|-------------|-------|
|         | Group A | Group B |       |
| primi   | 65      | 58      | 123   |
| % of GROUP | 65.0%   | 58.0%   | 61.5% |
| multi   | 35      | 42      | 77    |
| % of GROUP | 35.0%   | 42.0%   | 38.5% |
| Total   | 100     | 100     | 200   |
| % of GROUP | 100.0%  | 100.0%  | 100.0%|

Table 3 shows 65 patients in group A and 58 patients in group B are primigravida out of 100 patients each and remaining are multigravidas. This is statistically insignificant.

TABLE 4: GESTATIONAL AGE WISE DISTRIBUTION OF CASES

| GA     | GROUP | Total |
|--------|-------|-------|
|        | Group A | Group B |       |
| 16-20  | 16      | 18      | 34     |
| % of GROUP | 16.3%   | 18.0%   | 17.2%  |
| 21-24  | 33      | 26      | 59     |
| % of GROUP | 33.7%   | 26.0%   | 29.8%  |
| 25-28  | 26      | 24      | 50     |
| % of GROUP | 26.5%   | 24.0%   | 25.3%  |
| 29-32  | 23      | 32      | 55     |
| % of GROUP | 23.5%   | 32.0%   | 27.8%  |
| Total  | 98      | 100     | 198    |
| % of GROUP | 100.0%  | 100.0%  | 100.0% |
Table 4 shows mean gestational age in group A 25.9± 4.4 and in group B 26.1± 4.5. This is statistically insignificant.

**Table 5: Distribution of Cases According to Symptoms**

| SYMPTOM | GROUP     | Total |
|---------|-----------|-------|
|         | Group A   | Group B |       |
| GW      | Count     | 94     | 80    | 174   |
|         | % of GROUP| 94.0%   | 80.0% | 87.0% |
| GW+LOA  | Count     | 6      | 20    | 26    |
|         | % of GROUP| 6.0%   | 20.0% | 13.0% |
| Total   | Count     | 100    | 100   | 200   |
|         | % of GROUP| 100.0% | 100.0%| 100.0%|
Table 5 shows generalised weakness in 94 patients in group A and 80 patients in group B and remaining complained of loss of appetite along with generalised weakness. This is statistically insignificant.

Table 6: Distribution of cases according to signs

| SIGN | GROUP | GROUP A | GROUP B | Total |
|------|-------|---------|---------|-------|
| P    | Count | 79      | 74      | 153   |
| % of GROUP | 79.0% | 74.0% | 76.5% |
| P E   | Count | 10      | 11      | 21    |
| % of GROUP | 10.0% | 11.0% | 10.5% |
| P S   | Count | 7       | 11      | 20    |
| % of GROUP | 7.0% | 13.0% | 10.0% |
| P K   | Count | 4       | 2       | 6     |
| % of GROUP | 4.0% | 2.0% | 3.0% |
| Total | Count | 100     | 100     | 200   |
| % of GROUP | 100.0% | 100.0% | 100.0% |

Graph 6: Distribution of cases according to signs

Table 6 shows in group A 79 patients and in group B 74 patients has only pallor which is subjective observation and is insignificant.
**TABLE 7: DISTRIBUTION OF CASES ACCORDING TO ADVERSE REACTION**

| ADVERSE EFFECTS | GROUP | Total |
|-----------------|-------|-------|
|                 | Group A | Group B |     |
| None            | 71     | 93     | 164 |
| % of GROUP      | 71.0%  | 93.0%  | 82.0% |
| Nausea          | 19     | 0      | 19  |
| % of GROUP      | 19.9%  | 0%     | 9.5% |
| Gastritis       | 6      | 0      | 6   |
| % of GROUP      | 6.0%   | 0%     | 3.0% |
| Constipation    | 4      | 0      | 4   |
| % of GROUP      | 4.0%   | 0%     | 2.0% |
| Chills          | 6      | 5      | 5   |
| % of GROUP      | 0.0%   | 5.0%   | 2.5% |
| Thrombophlebitis| 2      | 2      | 2   |
| % of GROUP      | 0.0%   | 2.0%   | 1.0% |
| Total           | 100    | 100    | 200 |
| % of GROUP      | 100.0% | 100.0% | 100.0% |

**Graph 7: Distribution of cases according to adverse reaction**

Table 10: shows minor adverse reactions in 29 patients in group A and 7 patients in group B out of 100 patients which is statistically insignificant. They continued with the study.
TABLE 8: COMPARISON OF HEMOGLOBIN PERCENTAGE

| GROUP | Mean | Std. Deviation | N  |
|-------|------|----------------|----|
| HBPRE |      |                |    |
| Group A | 8.0800 | .53504  | 100 |
| Group B | 7.6570 | .50598  | 100 |
| Total   | 7.8685 | .56101  | 200 |
| HBPOST |      |                |    |
| Group A | 9.6620 | .85183  | 100 |
| Group B | 10.1871 | 1.43527 | 100 |
| Total   | 9.9247 | 1.20629 | 200 |

TABLE 9: COMPARISON OF Hct PERCENTAGE PRETREATMENT VS POSTTREATMENT

| GROUP | Mean  | Std. Deviation | N  |
|-------|-------|----------------|----|
| HCTPRE|      |                |    |
| Group A | 25.3600 | 1.15049  | 100 |
| Group B | 25.2710 | 2.71421  | 100 |
| Total   | 25.3155 | 2.07977  | 200 |
| HCTPOST|      |                |    |
| Group A | 27.9300 | 1.89766  | 100 |
| Group B | 32.4400 | 1.95050  | 100 |
| Total   | 30.1850 | 2.96559  | 200 |

Graph 8: Comparison of Hemoglobin Percentage

Table 10: Shows mean haemoglobin 8.08% pretreatment and 9.66% posttreatment in group A and therefore a rise by 1.68% in 4 weeks. The mean haemoglobin 7.66% pretreatment and 10.18% posttreatment in group B and therefore a rise by 2.66% in 4 weeks. This is statistically significant.
Table 9: shows mean haematocrit 25.36% pretreatment and 27.9% posttreatment in group A and therefore a rise by 2.5% in 4 weeks. The mean haematocrit 25.27% pretreatment and 32.4% posttreatment in group B and therefore a rise by 7.2% in 4 weeks. This is statistically significant.

Table 10: Comparison of MCV percentage pretreatment vs posttreatment

|          | GROUP | Mean  | Std. Deviation | N  |
|----------|-------|-------|----------------|----|
| MCVpre   | Group A | 65.6900 | 1.68592 | 100 |
|          | Group B | 67.9500 | 6.12888 | 100 |
|          | Total   | 66.8200 | 4.62434 | 200 |
| MCVpost  | Group A | 72.0900 | 1.71208 | 100 |
|          | Group B | 80.1400 | 4.75675 | 100 |
|          | Total   | 76.1150 | 5.38486 | 200 |

Table 10: shows mean MCV 65.69fl pretreatment and 72.09fl posttreatment in group B and therefore a rise by 6.4fl in 4 weeks. The mean MCV 67.95fl pretreatment and 80.14fl posttreatment in group B and therefore a rise by 12fl in 4 weeks. This is statistically significant.
DISCUSSION: Anemia due to iron deficiency is the commonest malnutrition disorder seen throughout the world and in India, affecting 35-75% (average 56%) of pregnant women in developing countries and 18% of women from industrialized countries are anemic. Currently there are many oral iron and intravenous preparations available. The traditional treatments, i.e., oral iron therapy and blood transfusion, involve significant drawbacks. High doses of oral iron frequently cause side effects, and noncompliance is common.

Administration of oral iron supplementations is not sufficient enough in order to reverse anemia promptly, due to the limited absorption, the gastrointestinal symptoms and the poor compliance for long treatment of the patients. As far as blood transfusions are concerned, because of the risk of infection (bacterial, viral, prions) and immunomodulation associated with allergenic blood products, especially in this young and otherwise healthy population, transfusions are used only in the most severe cases and particularly in life threatening situations.
Therefore, intravenous iron has been considered as an alternative in the management of iron deficiency anemia. This randomized trial is conducted in Obstetrics & Gynaecology Department of Cheluvamba Hospital of Mysore Medical College and Research Institute, Mysore. The aim of the study was to show that intravenous iron sucrose can be an alternative to oral ferrous sulphate in terms of safety, efficacy and compliance in treating anaemia in pregnancy. All these women were randomly assigned (100 women each) to receive either calculated dose of intravenous iron sucrose (Group B) or oral ferrous sulphate 200mg, BD per day (Group A).

The characteristics of patients in group A and in group B were statistically comparable in relation to age. In the study majority of women were in the age group of 21 - 25 years. Mean age of the patients in other studies were approximately similar to present study. In all the studies maximum number of patients were primigravidas. This is explained by high prevalence of iron deficiency anaemia in adult non-pregnant women (In our study group 61.5% were primigravidas).

When these anemic women become pregnant their anemia will be aggravated by increased need of iron during pregnancy, and it is important to screen iron deficiency anemia in all non-pregnant child bearing age group women as recommended by Centre of Disease Control and Prevention (CDC). In the present study the mean of gestational age at the time of inclusion in both the groups is comparable (in group A 25.92 ± 4.40 weeks and in group B 26.12 ± 4.5 weeks).

The mean of gestational age in the Aggarwal Rohina et al is 28.8 wks and 28.2 wks and Al Momen et al is 21.9 wks and 21.7 wks in oral and IV group respectively. Among 200 patients studied 79% and 74% showing presence of pallor on general physical examination in either groups respectively, most of other studies not commented as the parameter is more subjective. In our study, the mean baseline hemoglobin was 8.08 and 7.65 g/dl in oral and IV group respectively, which is found to be statistically insignificant between the groups.

Post treatment hemoglobin after 4 weeks showed a mean value of 9.6 gm/dl and 10.18 gm/dl in oral and IV group respectively (p value < 0.0001), which is statistically significant. The average rise of hemoglobin is 1.6 gm/dl and 2.6 gm/dl in oral and IV group respectively (p value 0.0001), which is statistically significant. In the Aggarwal Rohina et al study, baseline hemoglobin levels is 5.94 and 6.27 g/dl and in the Al Momen et al, baseline haemoglobin is 7.6 and 7.5 g/dl are studied. In the Aggarwal et al study, average rise of hemoglobin is 4.32 gm/dl and 5.03 gm/dl and in the Al Momen et al, average rise of haemoglobin is 3.54 g/dl and 5.3 g/dl in oral and IV group respectively.

The mean baseline Hct is 25.36% and 25.27% in oral and IV groups respectively. Post treatment Hct after 4 weeks showed, an average rise of Hct is 2.5% and 7.2% in oral and IV group respectively (p value 0.0001), which is statistically significant. The mean baseline MCV is 65.66 fl and 67.95 fl in oral and IV group respectively. Post treatment MCV after 4 weeks showed an average rise of 6.4 fl and 12 fl in oral and IV group respectively (p value 0.0001), which is statistically significant.

There are no serious adverse effects in the study, however 7% in IV group and 29% in oral group has minimal side effects, but continued with the study. Same observations reported in other studies like Al-Momen et al, Bayoumeu et al and Aggarwal Rohina et al, without serious adverse effects. There are no serious adverse effects in the study, however 7% in IV group and 29% in oral group has minimal side effects, but continued with the study. Same observations reported in other studies like Al-Momen et al, Bayoumeu et al and Aggarwal Rohina et al, without serious adverse effects. Compliance in the study is, for the most part, fairly high. There are no drop outs from the study and in the clinical setting it may be difficult to get the same rate of compliance for oral iron therapy.
Our study is comparable with other two studies. In a study done by Aggarwal Rohina S et al in 2010, showed baseline Hb 6.27 and 5.95g%, Hct 18.8 and 17.8%, MCV 71.28 and 70.1fl in IV and oral group respectively. After 4wks, Hb% increased to 11.3 and 10.26g%, Hct increased to 33.9 and 30.77% and MCV increased to 93 and 85.8fl in IV and oral group respectively. In another study done by Al Momen et al in 1996, showed baseline Hb 7.58 & 7.66g% and MCV 68.6 & 70.8fl in IV and oral group respectively. After 4wks Hb% increased to 12.8 & 11.1g% and MCV increased to 82.6 & 74.9fl in IV and oral group respectively. In both studies no major side effects is seen.

**SUMMARY:** This study is undertaken as a randomized control trial to compare the efficacy, safety and compliance of injectable iron sucrose with oral ferrous sulphate in the treatment of anaemia in pregnancy on an out-patient basis. Two hundred pregnant women with established diagnosis of iron deficiency anemia are included in the study. All these women are randomly assigned (100 women each) to receive either calculated dose of intravenous iron sucrose (Group B) or oral ferrous sulphate 200mg, BD per day (Group A).

**THE FOLLOWING OBSERVATIONS WERE MADE IN THE STUDY:**
1. The age distribution of the women in the both groups is statistically comparable. The majority of women were in the age group of 21 to 25 years.
2. Among the cases studied majority of them are booked cases as the OPD patients are taken for study.
3. Primigravidas comprised the maximum number of patients in both the groups.
4. Most of the women presented with symptom of generalised weakness.
5. The mean gestational age at the time of inclusion in both the groups is comparable (in group A 25.92±4.4weeks and in group B 26.12±4.50 weeks).
6. Among the groups, all patients showed presence of pallor on general physical examination in both oral and IV group.
7. The mean baseline hemoglobin is 8.08 and 7.6g/dl in oral group and IV group respectively, which is found to be statistically insignificant.
8. The percentage rise in hemoglobin at fourth weeks of treatment is statistically significant when compared to the baseline.
9. Statistically significant rise in hemoglobin, MCV and Hct levels are found at fourth week in IV group when compared to oral group.
10. None of the patients in the IV group had any of the dreaded side effects which are known to occur with intravenous preparations.
11. None of the patients from either group had failure of treatment.
12. None of the patients are excluded from the study.

**CONCLUSION:** This study concluded that intravenous iron sucrose is safe, highly efficacious with better compliance for the treatment of iron deficiency anemia in pregnancy. Iron sucrose therapy is more effective in achieving the optimum results, an increase in Hb concentrate, MCV levels and an increase in Hct %. Therefore it is a suitable alternative to oral iron. There were no treatment failures and none of them required blood transfusions.
BIBLIOGRAPHY:
1. UNICEF\UNO\WHO GENEVA 2001. Iron deficiency anaemia, assessment, prevention and control.
2. Cutner A. Failed response to treat anaemia in pregnancy reasons & evaluation. J Obstet Gynacol 1999 (Suppl): 523-7.
3. Theresa OS. Iron status during pregnancy: setting the stage for mother and infant. Am J Clin Nutr 2005: 81; 1218S-22S.
4. Scot BS. And George MR. Parental iron therapy option. Am J 2004: 76: 74-8.
5. Chandler G, Harchowal J, Macdougall IC. Intravenous iron sucrose: establishing a safe dose. Am J Kidn Dis 2001; 38: 988-91.
6. Mishra Vineet V, Evaluate iron sucrose and oral iron in management of IDA in pregnancy NJCM 2012; 93: 415-16.
7. Vidyadhar B Bangal, Compare oral iron versus intravenous iron sucrose in postpartum period. IJBAR 2012; 89: 102-08
8. Kochhar PK, Kaundal, Intravenous iron sucrose vs oral iron in iron deficiency anemia in pregnancy JOGR 2012; 42 (6): 114-20.
9. Sunayana Verma, Intravenous iron therapy versus oral iron in postpartum anemia JSFOG 2011; 3 (2): 67-70.
10. Surriaya Halima, Oral versus parenteral iron in anemic pregnant woman. GJMS 2011:9(5): 54-9.
11. Armond – Ugon R, Efficacy of intravenous iron for treating postpartum anemia. JWH 2011; 20 (1): 123-7.
12. Meghan, Crowely, Intravenous iron vs oral iron in the treatment of postpartum anemia. School of physician assistant studies 2010; 215: 24-28.
13. Giannoulis C et al Intravenous administration of iron sucrose for treating anemia in postpartum women HIPPOKRATIA 2009, 13, 1: 38-40.
14. Milman N, Bergholt T, Byg K, Eriksen L, Graudal N. Iron status and iron balance during pregnancy, a critical reappraisal of iron supplementation. Acta Obstet Gynecol Scand. 1999; 78: 749–57.
15. Westad S, Backe B, Salvesen KA, Nakling J, Okland I, Borthen I, Rognerud Jensen OH, Kolas T, Lokvik B, Smedvig E.A 12 week randomized study comparing intravenous iron sucrose verses oral ferrous sulphate for treatment of postpartum anemia, Acta Obstet Gynecol Scand. 2008; 87 (9): 916-23.
16. Bhandal N, Russell R. Intravenous versus oral iron therapy for postpartum anaemia. BJOG 2006; 113: 1248-1252.
17. Al RA, Unlubilgin E, Kandemir O, Yalvac S, Cakir L, Haberal A. Intravenous versus oral iron for treatment of anemia in pregnancy: a randomized trial. Obstet Gynecol 2005; 106: 1335-40
18. Khurshid Shabbir Raja, Intravenous iron sucrose complex in iron deficiency anemia in pregnancy, RWJ 2003; 216: 64-69.
19. Bayoumeu F, Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route AM J obstet gynecol 2002; 186: 518-212.
20. Wali A, Mushtaq A, Nilofer. Comparative study— efficacy, safety and compliance of intravenous iron sucrose and intramuscular iron sorbitol in iron deficiency anaemia of pregnancy. J Pak Med Assoc 2002; 52: 392-5.
21. Perewusny KG, Huck R, Huck A, Breymann C. Parenteral iron-sucrose complex. Br J Nutr 2002; 88: 3-10.
22. Carretti N, Paticchio MR. Intravenous iron therapy in pregnancy anemia: Gynecol Obstet Invest 1999; 47: 217-22.
23. Hallak M, Sharon AS, Diukman R, Auslender R, Abramovici H. Supplementing iron intravenously in pregnancy: a way to avoid blood transfusions. J Reprod Med 1997; 42: 99-103.
24. Al-Momen AK, al-Meshari A, al-Nuaim I, Saddique A, Abutalib Z, Khashogi T, et al. Intravenous iron sucrose complex in the treatment of iron deficiency anemia during pregnancy. Eur J Obstet Gynecol Reprod Biol 1996; 69: 121-4.
25. Ragip A, Intravenous versus oral iron for treatment of anemia in pregnancy, A randomized trial, ACOG 2005, Vol 106; No.6: 1335-40.
26. Ministry of Food and Civil Supplies, Food and Nutrition Board, Department of Food, National Workshop on Dietary and Nutritional Guidelines for food and agriculture planning, October 4-6, 1989, New Delhi.
27. Ministry of Women and Child Development, National Guidelines on Infant and Young Child Feeding, Government of India, 2006.
28. Goodman & Gilman's the Pharmacological basis of therapeutics - 11th ed. (2006).
29. Bayoumeu F, Iron therapy in iron deficiency anemia in pregnancy: intravenous route versus oral route AM J obstet gynecol 2002; 186: 518-212.
30. Zutschi V, Batra S, Ahmed SS, Khera W, Chauhan G, Ghandi G, et al injectable iron supplementation instead of oral iron. J obstet and gynaecol India 2004; 54; 37-8.
31. Prema K Ramalakshmi BA, Macharapeddi K, Babu S, Effect of iron therapy in anemic pregnant women. Indian J med Res 1982; 75: 534-40.
32. Singh K, Pong YF, Kuperan P. A comparison between intravenous iron polymaltose complex (Ferrum Hausmann) and oral ferrous fumarate in the treatment of iron deficiency anemia in pregnancy. Eur J Haematol 1998; 60 (2): 119-24.
33. A. Kumar et al. Oral versus high dose parenteral iron supplementation in pregnancy. International Journal of Gynecology and Obstetrics (2005) 89, 7-13.
34. Silverstein SB, Rodgers GM. Parenteral iron therapy options. Am J Hematol 2004; 76: 74-8.
35. Giannoulis C et al Intravenous administration of iron sucrose for treating anemia in postpartum women HIPPOKRATIA 2009, 13, 1: 38-40.
36. Beshara S, Lundqvist H, Sundin J, Lubberink M, Tolmachev V, Valind S, et al. Pharmacokinetics and red cell utilization of iron (III) hydroxide-sucrose complex in anaemic patients: a study using positron emission tomography. Br J Haematol 1999; 104: 296-302.
37. Kumpf VJ. Parenteral iron supplementation. Nutr Clin Prac 1996; 11 (4): 139-46.
38. Protocol for the use of IV iron sucrose - Venofer® Page 2 of 11 Author: Transfusion Practitioner V1.0 Approved by D&TC 23 January 2008.
39. Rukhsana Ayub et al. Efficacy and Safety of Total Dose Infusion of Low Molecular Weight Iron Dextran in the Treatment of Iron Deficiency Anemia during Pregnancy. Journal of the College of Physicians and Surgeons Pakistan 2008, Vol. 18 (7): 424-427.
40. Williams WJ, Beutler E, Erslev AJ, Lichtman MA. Haematology 3rd ed. McGraw-Hill; 1983.
41. McKenzie SB. Clinical Laboratory Hematology, vol 2. Pearson Prentice Hall, Upper Saddle River, New Jersey 07458; 2004.
42. Barut et al. Intravenous iron treatment of anemia in pregnancy. J Turkish German Gynecol Assoc 2009; 10: 109-15.
43. A Bashiri, Anemia during pregnancy and treatment with intravenous iron: review of the literature, Euro Journal of Obstetrics and Gynecology and Reprod Biol 2003, Vol 110, Issue: 2.
44. F. Gary Cunningham, Hematological Disorders, William’s Obstetrics, McGraw Hill, 22nd edition p. 1144, 1145.
45. Fernando Arias, Practical guide to high risk pregnancy and delivery, 2nd edition, p. 245.
46. Dutta DC. Medical illness complicating pregnancy. Textbook of Obstetrics, 6th edition. [Ed Konar H] The central Book Agency Pvt Ltd. Culcutta: 2004; p262- 271.
47. Breymann C, Renate Huch. Anemia in pregnancy and puerperium, 2011, 4th edition, chapter. 2: p20–25.
48. Renu Mishra, Ian Donald’s Practical Obstetric problems, 6th edition 2010, chapter anemia: p148-50.

AUTHORS:
1. Shireen A.
2. S. Radhamani

PARTICULARS OF CONTRIBUTORS:
1. Resident, Department of OBG, Mysore MMCRI, Mysore.
2. Professor, Department of OBG, Mysore MMCRI, Mysore.

NAME ADDRESS EMAIL ID OF THE CORRESPONDING AUTHOR:
Dr. Shireen A,
# 803B, Doctors Quarters,
MIMS, Mandya,
Karnataka.
Email: karani_gk@gmail.com

Date of Submission: 22/10/2014.
Date of Peer Review: 23/10/2014.
Date of Acceptance: 30/10/2014.
Date of Publishing: 30/10/2014.